公开(公告)号：US20220280501A1

公开(公告)日：2022-09-08

申请号：US17685138

申请日：2022-03-02

Applicant: Universitätsspital Basel

Inventor： Matthias Emanuel LIECHTI ,  Patrick Raphael VIZELI

IPC: A61K31/4745 ,  C12Q1/6876

Abstract: A method of dosing LSD in treating patients, by assessing genetic characteristics in the patient before LSD use, administering LSD to the patient based on the patient genetics, and producing maximum positive subjective acute effects in the subject and/or reducing anxiety and negative effects. A method of determining a preferred dose of LSD, by determining metabolic and genetic markers in a patient (such as by assessing CYP2D6 activity and/or assessing 5HTR1A rs6295 and 5HTR2A rs6313 genotypes in a patient), adjusting a dose of LSD based on the metabolic activity and genetic profile, administering the dose of LSD to the patient, and producing maximum positive subjective acute effects in the subject and/or reducing anxiety and negative effects. A method of determining a dose of LSD based on an assessment of the presence of CYP2D6 inhibitors.

公开(公告)号：US20220273628A1

公开(公告)日：2022-09-01

申请号：US17672670

申请日：2022-02-15

Applicant: Universitätsspital Basel

Inventor： Matthias Emanuel LIECHTI ,  Friederike Sophie HOLZE

IPC: A61K31/437 ,  A61K45/06 ,  A61P25/22

Abstract: A method of treating anxiety disorders specifically not associated with causes such as a life-threatening serious somatic illness, by administering a psychedelic to an individual, and treating anxiety and specifically causing reductions in the rating scale score measures of anxiety (STAI global or state or trait anxiety) and/or measures of depression (HDRS or BDI scores) and/or measures of general psychological distress (SCL-90 ratings) in the patient for several weeks beyond administration of the psychedelic. A method of treating anxiety, by administering a psychedelic (preferably LSD) to an individual having anxiety not associated with causes such as a life-threatening serious somatic illness, and inducing positive acute drug effects and positive long-term therapeutic effects in the individual.

公开(公告)号：US20250152565A1

公开(公告)日：2025-05-15

申请号：US19020135

申请日：2025-01-14

Applicant: UNIVERSITÄTSSPITAL BASEL

Inventor： Matthias Emanuel LIECHTI ,  Friederike Sophie HOLZE

IPC: A61K31/437 ,  A61K45/06 ,  A61P25/22

Abstract: A method of treating anxiety disorders specifically not associated with causes such as a life-threatening serious somatic illness, by administering a psychedelic to an individual, and treating anxiety and specifically causing reductions in the rating scale score measures of anxiety (STAI global or state or trait anxiety) and/or measures of depression (HDRS or BDI scores) and/or measures of general psychological distress (SCL-90 ratings) in the patient for several weeks beyond administration of the psychedelic. A method of treating anxiety, by administering a psychedelic (preferably LSD) to an individual having anxiety not associated with causes such as a life-threatening serious somatic illness, and inducing positive acute drug effects and positive long-term therapeutic effects in the individual.

公开(公告)号：US20230000799A1

公开(公告)日：2023-01-05

申请号：US17883502

申请日：2022-08-08

Applicant: Universitätsspital Basel

Inventor： Matthias Emanuel LIECHTI

IPC: A61K31/137 ,  A61P25/00

Abstract: A method of inducing psychedelic states in an individual, by administering mescaline, a salt thereof, analogs thereof, or derivatives thereof to the individual, and inducing a psychedelic state in the individual. A method of therapy, by administering an intermediate “good effect dose” of mescaline, salt of mescaline, analogs thereof, or derivatives thereof to an individual, and inducing positive acute drug effects that are known to be associated with more positive long-term responses in psychiatric patients. A method of therapy, by administering an “ego-dissolution” dose of mescaline, a salt of mescaline, analogs thereof, or derivatives thereof to an individual, and providing the experience of ego-dissolution.

公开(公告)号：US20230039395A1

公开(公告)日：2023-02-09

申请号：US17734601

申请日：2022-05-02

Applicant: Universitätsspital Basel

Inventor： Matthias Emanuel LIECHTI ,  Friederike Sophie HOLZE

IPC: A61K49/00 ,  A61K31/48 ,  A61K31/675

Abstract: A method of treating a patient with a psychedelic, by administering either a dose of LSD to the patient that is equivalent to a known dose of psilocybin with desired acute and therapeutic effects, or administering a dose of psilocybin to the patient that is equivalent to a known dose of LSD with desired acute and therapeutic effects. A method of treating a patient with LSD, by administering a dose of LSD to the patient equivalent to those of psilocybin known to be associated with positive long-term therapeutic outcomes. A method of determining a dose of a psychedelic or the dose-equivalence to another psychedelic to be administered to an individual, by administering a dose of a psychedelic to an individual, determining positive acute effects and negative acute effects in the individual, and adjusting the dose to provide more positive acute effects than negative acute effects in the individual.

公开(公告)号：US20220387456A1

公开(公告)日：2022-12-08

申请号：US17692105

申请日：2022-03-10

Applicant: Universitätsspital Basel

Inventor： Matthias Emanuel LIECHTI ,  Anna Margarete BECKER

IPC: A61K31/675 ,  A61K31/343 ,  A61P25/24 ,  A61P25/22

Abstract: A method of enhancing positive effects of a psychedelic, by pretreating an individual with an antidepressant, administering a psychedelic to the individual, and inducing a more positive psychological state in the individual with the antidepressant-psychedelic combination compared with the psychedelic alone. A method of enhancing positive effects of a psychedelic, by inhibiting serotonin transport in an individual, increasing levels of endogenous monoamines in the individual, and stimulating 5-HT2A receptors in the individual. A composition including an antidepressant and a psychedelic in the same dosage form.

公开(公告)号：US20220265582A1

公开(公告)日：2022-08-25

申请号：US17675894

申请日：2022-02-18

Applicant: Universitätsspital Basel

Inventor： Matthias Emanuel LIECHTI

IPC: A61K31/137 ,  A61P25/00

Abstract: A method of inducing psychedelic states in an individual, by administering mescaline, a salt thereof, analogs thereof, or derivatives thereof to the individual, and inducing a psychedelic state in the individual. A method of therapy, by administering an intermediate “good effect dose” of mescaline, salt of mescaline, analogs thereof, or derivatives thereof to an individual, and inducing positive acute drug effects that are known to be associated with more positive long-term responses in psychiatric patients. A method of therapy, by administering an “ego-dissolution” dose of mescaline, a salt of mescaline, analogs thereof, or derivatives thereof to an individual, and providing the experience of ego-dissolution.

公开(公告)号：US20210346341A1

公开(公告)日：2021-11-11

申请号：US17238088

申请日：2021-04-22

Applicant: Universitätsspital Basel

Inventor： Matthias Emanuel LIECHTI

IPC: A61K31/36 ,  A61K31/48 ,  A61P25/22

Abstract: A method of enhancing positive effects of a psychedelic, by inducing a positive psychological state in an individual with an empathogen/entactogen, administering a psychedelic to the individual, and enhancing a positive response to the psychedelic. A composition including an entactogen/empathogen and a serotonergic psychedelic in the same dosage form or administered as separate compositions within a combination treatment schedule. A method of enhancing positive effects of a psychedelic, by inducing the release of endogenous monoamines, and subsequently stimulating 5-HT2A receptors.

公开(公告)号：US20220347169A1

公开(公告)日：2022-11-03

申请号：US17869896

申请日：2022-07-21

Applicant: Universitätsspital Basel

Inventor： Matthias Emanuel LIECHTI ,  Patrick Raphael VIZELI

IPC: A61K31/4745 ,  C12Q1/6876

Abstract: A method of dosing LSD in treating patients, by assessing genetic characteristics in the patient by identifying polymorphisms of CYP2D6 before use of a composition chosen from the group consisting of LSD, analogs thereof, derivatives thereof, and salts thereof, administering the composition to the patient based on the patient genetics, wherein a 50% dose is administered in a patient with non-functional CYP2D6 compared to a dose in functional CYP2D6 individuals, and producing maximum positive subjective acute effects in the patient and/or reducing anxiety and negative effects. A method of determining a preferred dose of LSD.

公开(公告)号：US20210267977A1

公开(公告)日：2021-09-02

申请号：US17156233

申请日：2021-01-22

Applicant: Universitätsspital Basel

Inventor： Matthias Emanuel LIECHTI

IPC: A61K31/517 ,  A61K31/48 ,  A61P25/26

Abstract: A composition for treating an individual while reducing acute effects, including effective amounts of a psychedelic drug and a duration shortening agent. A method of treating an individual with a psychedelic drug and reducing its acute duration of action, by administering a psychedelic drug to the individual, administering a duration shortening agent to the individual, and shortening and/or reducing the acute effects of the psychedelic drug. A method of stopping the acute duration of action of a psychedelic drug in an individual, by administering a duration shortening agent to the individual after the individual has taken a psychedelic drug and stopping the acute effects of the psychedelic drug.